SINGAPORE: Singapore reported nine new COVID-19 cases as of noon on Thursday (Dec 3), including one locally transmitted infection.
The local case is a dormitory resident and was asymptomatic. The man, known as Case 58443, was detected through surveillance, said the Ministry of Health (MOH).
"His polymerase chain reaction test yielded a very high Ct (cycle threshold) value, which is indicative of a low viral load. All his close contacts at the dormitory and his workplace have been isolated and placed on quarantine," added the ministry.
The rest of the infections are imported cases and were placed on stay-home notice upon arrival in Singapore. They were all asymptomatic.
READ: HSA evaluating initial data on COVID-19 vaccine submitted by Moderna for use in Singapore
The imported cases include a Singaporean and two permanent residents who returned from the United States. Another two cases are work pass holders currently employed in Singapore who arrived from Nepal.
The remaining cases include a dependant’s pass holder who arrived from France, and two short-term visit pass holders who arrived from Indonesia - one to visit Singaporean family members and the other to visit her fiance.
There were no new cases in the community.
MOH said the overall number of new cases in the community has remained low, with a total of four cases in the past week who are currently unlinked. More details can be found in the health ministry's daily situation report.
ONE MORE PATIENT DISCHARGED
One more case was discharged from the hospital, bringing Singapore's total recoveries to 58,145.
There are 26 cases still in hospital. Most of them are stable or improving, and no one is in the intensive care unit. Another 39 are being isolated and cared for at community facilities.
Twenty-nine people have passed away from complications due to COVID-19 infection.
As of Thursday, Singapore has reported a total of 58,239 COVID-19 cases.
HSA EVALUATING DATA ON COVID-19 VACCINE SUBMITTED BY MODERNA
Moderna has started submitting initial data on its COVID-19 vaccine candidate to the Health Sciences Authority (HSA), said the authority on Wednesday.
This is part of the process to evaluate its suitability for use in Singapore.
The biotechnology company “will continue to roll in data as soon as they become available”, as agreed with the authority, said HSA.
A rolling review, or rolling submission, process allows companies to submit real-time data from ongoing studies of the vaccine while the regulatory review is conducted simultaneously.
HSA said it has already started evaluating the available data submitted by Moderna to ensure “expeditious review”.
On Monday, Moderna announced it was “forging ahead” with the rolling review process for approval with HSA.
Moderna said that its vaccine was 94.1 per cent effective against COVID-19 and 100 per cent effective in preventing severe cases following the results of a late-stage Phase 3 study.
BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments
Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram
Article From & Read More ( 9 new COVID-19 cases in Singapore, including 1 locally transmitted infection - CNA )https://ift.tt/3mFZDtE
Business
No comments:
Post a Comment